1.72% -0.1331

비르 바이오테크 (VIR)

Vir Biotechnology Inc 주식(VIR)의 최신 뉴스

비르 바이오테크 (VIR)

Vir Biotechnology Inc 주식(VIR)의 최신 뉴스

Biopharma Layoff Tracker 2024: Biosense Webster, Charles River Laboratories, Vesigen and More Cut Staff - BioSpace

How to Take Advantage of moves in (VIR) - Stock Traders Daily

Vir Biotechnology names new CFO to boost financial strategy By Investing.com - Investing.com Australia

Vir Biotechnology (NASDAQ:VIR) Shares Gap Up to $7.82 - MarketBeat

Janet Napolitano Sells 12,190 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock - MarketBeat

Vir Biotechnology closes Sanofi licence deal for T-cell engagers - Pharmaceutical Technology

Vir Biotechnology Names Jason O’Byrne as Chief Financial Officer - TechBullion

Vir Biotechnology names new CFO to boost financial strategy - Investing.com

Vir Biotechnology names new CFO to boost financial strategy By Investing.com - Investing.com Canada

Vir Biotechnology names new CFO to boost financial strategy By Investing.com - Investing.com UK

Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer - Business Wire

Vir Biotechnology secures Sanofi cancer drug licenses By Investing.com - Investing.com Australia

Vir Biotechnology (NASDAQ:VIR) Trading Down 3.5% - MarketBeat

Vir Biotechnology secures Sanofi cancer drug licenses - Investing.com India

Vir Biotechnology secures Sanofi cancer drug licenses - Investing.com

Vir Biotechnology secures Sanofi cancer drug licenses By Investing.com - Investing.com Canada

Vir Biotechnology secures Sanofi cancer drug licenses By Investing.com - Investing.com UK

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers - Business Wire

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans? - Simply Wall St

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $33.00 Consensus PT from Analysts - MarketBeat

Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week Low at $7.61 - MarketBeat

Vir Biotechnology stock hits 52-week low at $7.61 - Investing.com

Vir Biotechnology stock hits 52-week low at $7.61 By Investing.com - Investing.com UK

Vir Biotechnology Becomes Oversold (VIR) - Nasdaq

Vir Biotechnology’s License Agreement with Sanofi - Global Legal Chronicle

Chronic Hepatitis B Market to Exhibit Moderate Growth Rate During the Forecast Period | Gilead, Ionis, GSK, Janssen, Dicerna, Roche, Vir Biotech - Barchart

HC Wainwright Weighs in on Vir Biotechnology, Inc.'s Q3 2024 Earnings (NASDAQ:VIR) - MarketBeat

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - StockTitan

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - Business Wire

Vir Biotechnology (NASDAQ:VIR) Rating Reiterated by HC Wainwright - MarketBeat

H.C. Wainwright sees regulatory wins boosting Vir Biotechnology stock potential - Investing.com Canada

Head-To-Head Survey: Recursion Pharmaceuticals (NASDAQ:RXRX) and Vir Biotechnology (NASDAQ:VIR) - Defense World

Comerica Bank Sells 2,990 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

California State Teachers Retirement System Lowers Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Price T Rowe Associates Inc. MD - Defense World

Vir evolves from antiviral one-stop shop to protein engineering play - BioCentury

Analysts Set Vir Biotechnology, Inc. (NASDAQ:VIR) PT at $33.00 - MarketBeat

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

34,750 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Purchased by Tidal Investments LLC - Defense World

VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024 - MSN

Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High? - MSN

San Francisco biotech companies slash hundreds of jobs amid restructuring wave - San Francisco Chronicle

Finance Watch: Vir Restructures, Adds Sanofi Cancer Drugs To Clinical-Stage Pipeline - Scrip

Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High? - Yahoo Finance

Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High? - Nasdaq

Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024 - 24/7 Wall St.

Vir Bio trims staff and pipeline to focus on Sanofi-licensed programmes - Yahoo Finance

Vir Biotechnology (NASDAQ:VIR) Trading Down 7.9% - MarketBeat

Vir Biotechnology (NASDAQ:VIR) Releases Earnings Results, Misses Expectations By $0.13 EPS - Defense World

Vanguard Group Inc. Has $125.36 Million Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat

Barclays Increases Vir Biotechnology (NASDAQ:VIR) Price Target to $28.00 - Defense World

Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results - Simply Wall St

Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2024 Earnings Call Transcript - Insider Monkey

Vir Biotechnology (NASDAQ:VIR) Releases Quarterly Earnings Results, Misses Estimates By $0.13 EPS - MarketBeat

VIR과 유사한 종목